论文部分内容阅读
目的探讨不孕症妇女支原体感染状况及耐药性分析。方法对480例就诊的不孕症妇女(不孕组)进行支原体培养及药敏试验,并选择120例正常早孕妇女作为对照(对照组)。结果不孕组480例患者支原体培养结果阳性232例,阳性率为48.3%,其中单纯UU阳性164例,单纯MH阳性40例,UU和MH均阳性28例;对照组120例正常早孕妇女支原体培养结果阳性32例,阳性率为26.67%,其中单纯UU阳性21例,单纯MH阳性6例,UU和MH均阳性5例。不孕组支原体的阳性率明显高于对照组(χ2=18.29,P<0.01)。不孕组232株支原体的药敏结果显示米诺环素、多西环素,敏感率均>90%;耐药率最高的是喹诺酮类抗生素,依次为司帕沙星、氧氟沙星、诺氟沙星,耐药率均>50%,其中对司帕沙星的耐药率最高达58.62%。结论支原体感染可能是引起不孕的主要原因之一。支原体对米诺环素、多西环素等四环素族高度敏感,对喹诺酮类和大环内酯类抗生素的敏感性下降。临床上对支原体感染的治疗,应常规进行培养及药敏试验,根据药敏结果选择合适的抗菌药物进行治疗。
Objective To investigate the prevalence and drug resistance of mycoplasma in infertile women. Methods 480 infertile women (infertility group) were enrolled in mycoplasma culture and drug sensitivity test, and 120 normal pregnant women were selected as the control group (control group). Results In infertility group, 232 cases of mycoplasma were positive, with a positive rate of 48.3%. Among them, 164 cases were purely UU positive, 40 cases were pure MH, 28 cases were positive for both UU and MH. In the control group, 120 cases of normal pregnant women were infected with mycoplasma The results were positive in 32 cases, the positive rate was 26.67%, of which 21 were simple UU positive, 6 were positive for pure MH, 5 were positive for both UU and MH. The positive rate of mycoplasma in infertility group was significantly higher than that in control group (χ2 = 18.29, P <0.01). The susceptibility results of 232 mycoplasma in infertility group showed that minocycline and doxycycline were both sensitive> 90%. The highest quinolone antibiotics were sparfloxacin, ofloxacin, Norfloxacin, the resistance rates were> 50%, of which sparfloxacin resistance rates up to 58.62%. Conclusion Mycoplasma infection may be one of the main causes of infertility. Mycoplasma for minocycline, doxycycline and other tetracyclines highly sensitive to quinolones and macrolide antibiotics decreased sensitivity. Clinical treatment of mycoplasma infection should be routine culture and drug susceptibility testing, drug susceptibility results based on the selection of appropriate antimicrobial drugs for treatment.